/PRNewswire/ -- The first-ever drug known to prevent some preterm births, which won market approval today from the Food and Drug Administration, was welcomed by the March of Dimes.
"For the first time, we have an FDA-approved treatment to offer women who have delivered a baby too soon, giving them hope that their next child will have a better chance at a healthy start in life," said Alan Fleischman, MD, senior vice president and medical director of the March of Dimes. "Women who already have had a baby born prematurely should check with their health care provider to see if this treatment is appropriate for them. This treatment is not for everyone."
The FDA approved hydroxyprogesterone caproate injection, commonly known as 17P, which is a synthetic form of a hormone produced during pregnancy. It will be marketed under the brand name Makena™ and given in weekly injections to pregnant women between 16 and 20 weeks gestation and continuing until 37 weeks gestation.
A published study by the March of Dimes, the National Institutes for Health, and the Centers for Disease Control and Prevention, using data from 2002, estimated that if all women eligible for the progesterone injections received them, nearly 10,000 spontaneous premature births might be prevented each year.
Nikki and Densel Fleming's first child, Lauren, was born 3 1/2 months early, weighing only two pounds, one ounce. Lauren was hospitalized for five months, a scary and agonizing time for the Marvin, N.C. couple. Although they wanted a bigger family, the Flemings knew Lauren's early birth increased the chance that future babies also would be born too soon. Nikki received weekly progesterone injections for her next two pregnancies and their next two children, Erin and Corbin, were born nearly full term.
"I thank the March of Dimes for making high-risk pregnant women aware of progesterone treatments because, in my heart, I know that the weekly injections I received while pregnant, combined with the knowledge doctors now have about the causes and signs of preterm labor, helped Erin and Corbin be born full term," said Nikki Fleming.
Since 2003, the American Congress of Obstetricians and Gynecologists has recommended that doctors offer progesterone treatments to high-risk women.
Prior to today's approval of Makena, health care providers ordered prescriptions of 17P from compounding pharmacies; however, many eligible patients faced logistical and financial barriers to access. FDA approval means the drug now will be widely available only in specialty pharmacies and that there will be improved access of the drug through healthcare coverage.
The drug is approved for use by women pregnant with one baby and who already have a baby who was born before 37 weeks of pregnancy either because labor began on its own, without drugs or other methods, or because the membranes surrounding the baby ruptured too early.
In the United States, more than half a million babies are born preterm each year. Preterm birth, birth before 37 weeks of pregnancy, is a serious health problem that costs the United States more than $26 billion annually, according to the Institute of Medicine. It is the leading cause of newborn death, and babies who survive an early birth often face the risk of lifetime health challenges, such as breathing problems, cerebral palsy, intellectual disabilities and others. Even infants born just a few weeks early have higher rates of hospitalization and illness than full-term infants. The last few weeks of pregnancy are critical to a baby's health because many important organs, including the brain and lungs, are not completely developed until then.
The March of Dimes is the leading nonprofit organization for pregnancy and baby health. With chapters nationwide, the March of Dimes works to improve the health of babies by preventing birth defects, premature birth and infant mortality. For the latest resources and information, visit marchofdimes.com or nacersano.org. Find us on Facebook and follow us on Twitter.
The March for Babies is sponsored nationally by the March of Dimes number one corporate supporter Kmart, Farmers Insurance Group, Bayer HealthCare, CIGNA, United Airlines, Famous Footwear, FedEx, Sanofi Pasteur, First Response, and Mission Pharmacal. To join an event near you, visit marchforbabies.org.
----
Community News You Can Use
Click to read MORE news:
www.GeorgiaFrontPage.com
Twitter: @gafrontpage & @TheGATable @HookedonHistory
www.ArtsAcrossGeorgia.com
Twitter: @artsacrossga, @softnblue, @RimbomboAAG @FayetteFP
Friday, February 04, 2011
March of Dimes Welcomes FDA Approval of Progesterone Injections
at
9:53 AM
Labels: 17P, approval, births, fayette front page, fda, georgia, georgia front page, gestational, hormone, injection, makena, premature, preterm, progesterone
Wednesday, January 05, 2011
FDA to Require Substantial Equivalence Reviews for New Tobacco Products
/PRNewswire/ -- The U.S. Food and Drug Administration announced today that certain tobacco products introduced or changed after Feb. 15, 2007 must be reviewed by the agency. In FDA guidance published today, the agency outlines a pathway for marketing a product whereby the company marketing the product must prove that it is "substantially equivalent" to products commercially available on Feb. 15, 2007.
"Substantially equivalent" means the products must be the same in terms of ingredients, design, composition, heating source and other characteristics to an existing, single predicate product or have different characteristics, but not raise different questions of public health.
"This specific part of the law is meant to ensure that new tobacco products are evaluated by the FDA before they are cleared to enter the marketplace. The law requires FDA to carefully examine the impact those products may have on the public health," said Lawrence R. Deyton, M.S.P.H., M.D., director of the agency's Center for Tobacco Products. "Products that are equivalent to those which were on the market on February 15, 2007, may be cleared to go to market; those that are not may be prohibited from the market, or withdrawn if they are already available, if the changes raise different questions of public health."
"This piece of the Tobacco Control Act protects the health of all Americans," said Health and Human Services Secretary Kathleen Sebelius. "It does this by setting a clear deadline for tobacco companies to provide important product information to the FDA so the agency can then begin evaluating tobacco products for any potential new risks to public health."
The Family Smoking Prevention and Tobacco Control Act, which became law Jun. 22, 2009, granted the FDA regulatory authority over tobacco products. Generally, the law allows the FDA to deny applications for new products if marketing the product poses a harm to public health. FDA may deny applications for substantial equivalence if the marketing of that modified product would raise different questions of public health. An example would be a product that poses an increased health risk to users of the product or to nonusers by causing more of them to start smoking.
In general, in order to continue to market these products, manufacturers of tobacco products that were introduced or changed after Feb. 15, 2007, which include cigarettes, roll-your-own tobacco and all smokeless products must apply for equivalency by Mar. 22, 2011. Manufacturers intending to introduce new products into the market after that date must submit an application for the new product and obtain a marketing order from the FDA before introducing the product to market.
"No known existing tobacco product is safe, and a market order issued by the FDA for these products should never be interpreted as such," said Deyton. "One of the FDA's missions required by this new law is to ensure new products do not pose an increased threat to the American public. These products will not be safer, but we are required by this law to not allow even more dangerous products to cause further harm to those Americans who use tobacco products."
FDA also intends to issue guidance on materials the agency believes would show that a tobacco product was on the market on Feb. 15, 2007, as well as hold a Webinar Series in order to provide more assistance to manufacturers.
Information on the Webinar Series (available soon) and application process details and answers to questions can be found here:
http://www.fda.gov/TobaccoProducts/ResourcesforYou/ForIndustry/ucm238891.htm
-----
Community News You Can Use
Click to read MORE news:
www.GeorgiaFrontPage.com
Twitter: @gafrontpage & @TheGATable @HookedonHistory
www.ArtsAcrossGeorgia.com
Twitter: @artsacrossga, @softnblue, @RimbomboAAG @FayetteFP
at
11:29 AM
Labels: equivalent, fda, georgia, georgia front page, products, review, tobacco
Wednesday, November 10, 2010
HHS announces new tobacco strategy and proposed new warnings and graphics for cigarette packs and advertisements
U.S. Department of Health and Human Services today unveiled a new comprehensive tobacco control strategy that includes proposed new bolder health warnings on cigarette packages and advertisements. Once final, these health warnings on cigarettes and in cigarette advertisements will be the most significant change in more than 25 years. These actions are part of a broader strategy that will help tobacco users quit and prevent children from starting.
Tobacco use is the leading cause of premature and preventable death in the United States, responsible for 443,000 deaths each year. Thirty percent of all cancer deaths are due to tobacco. Each day 1,200 lives of current and former smokers are lost prematurely due to tobacco-related diseases.
“Every day, almost 4,000 youth try a cigarette for the first time and 1,000 youth become regular, daily smokers,” said HHS Secretary Kathleen Sebelius. “Today marks an important milestone in protecting our children and the health of the American public.”
The strategy includes a proposal issued by the Food and Drug Administration titled Required Warnings for Cigarette Packages and Advertisements. Specifically, the proposed rule details a requirement of the Family Smoking Prevention and Tobacco Control Act that nine new larger and more noticeable textual warning statements and color graphic images depicting the negative health consequences of smoking appear on cigarette packages and in cigarette advertisements. The public has an opportunity to comment on 36 proposed images through January 9, 2011.
By June 22, 2011, FDA will select the final nine graphic and textual warning statements after a comprehensive review of the relevant scientific literature, the public comments, and results from an 18,000 person study. Implementation of the final rule (September 22, 2012) will ultimately prohibit companies from manufacturing cigarettes without new graphic health warnings on their packages for sale or distribution in the United States. In addition, manufacturers, importers, distributors and retailers will no longer be allowed to advertise cigarettes without the new graphic health warnings in the United States. By October 22, 2012, manufacturers can no longer distribute cigarettes for sale in the United States that do not display the new graphic health warnings.
“Today, FDA takes a crucial step toward reducing the tremendous toll of illness and death caused by tobacco use by proposing to dramatically change how cigarette packages and advertising look in this country. When the rule takes effect, the health consequences of smoking will be obvious every time someone picks up a pack of cigarettes,” said FDA Commissioner Margaret A. Hamburg, M.D. ” This is a concrete example of how FDA’s new responsibilities for tobacco product regulation can benefit the public’s health.”
The FDA action is part of a broad department-wide strategy that was announced by Assistant Secretary for Health Howard K. Koh, M.D., MPH. While progress has been made, smoking remains particularly high with low-income and within certain racial/ethnic groups and in certain populations, including people with mental illnesses and substance abuse disorders. Ending the Tobacco Epidemic: A Tobacco Control strategic Action Plan outlines specific, evidence-based actions that will help create a society free of tobacco-related death and disease.
“We are at an unprecedented time in our nation’s history to protect the public’s health from tobacco use, the leading cause of preventable, premature death in the United States,” said Dr. Koh. “It will take renewed commitment from every sector of society to end the tobacco epidemic.”
In addition to the announcements made today, other recent tobacco control and prevention efforts include:
The Affordable Care Act is giving Americans in private and public health plans access to recommended preventive care, like tobacco use cessation, at no additional cost.
The American Recovery and Reinvestment Act (ARRA) invested $225 million to support local, state and national efforts to promote comprehensive tobacco control and expand tobacco quitlines.
The Prevent All Cigarette Trafficking Act (PACT) aims to stop the illegal sale of tobacco products over the Internet and through mail order, including the illegal sale to youth.
The Family Smoking Prevention and Tobacco Control Act (FSPTCA) gives FDA the authority to regulate the manufacture, marketing and distribution of tobacco products. Significant progress has already been made by restricting the use of the terms “light,” “low,” and “mild,” banning characterizing fruit, candy, and spice, flavors from cigarettes, and putting in place restrictions on the sale and distribution of cigarettes and smokeless tobacco products to youth.
The Children’s Health Insurance Program Reauthorization Act (CHIPRA) raised the federal cigarette tax by 62 cents per pack. Raising the price of tobacco products is a proven way to reduce tobacco use, especially among price-sensitive populations such as youth.
-----
Community News You Can Use
Click to read MORE news:
www.GeorgiaFrontPage.com
Twitter: @gafrontpage & @TheGATable @HookedonHistory
www.ArtsAcrossGeorgia.com
Twitter: @artsacrossga, @softnblue, @RimbomboAAG
www.FayetteFrontPage.com
Twitter: @FayetteFP
at
9:29 AM
Labels: advertisement, cigarette, control, fayette front page, fda, georgia, georgia front page, health, strateby, tobacco, warnings
Tuesday, July 20, 2010
FDA Warns Consumers, Pharmacists, and Wholesalers Not to Use Stolen Advair Diskus Inhalers
The FDA is warning the public that certain Advair Diskus inhalers stolen from a distribution warehouse in 2009 have been found in some pharmacies. The safety and effectiveness of the stolen inhalers cannot be assured and they should not be used.
Advair Diskus (fluticasone propionate and salmeterol inhalation powder) is an inhalerused to treat patients with asthma and chronic obstructive pulmonary disease.
The products were reported stolen in August 2009 from a GlaxoSmithKline warehouse near Richmond, Va. The inhalers found recently were the first from the stolen lots to be found in commerce. However, more stolen product may still be on the market and the FDA continues to aggressively investigate the matter.
Stolen medicine may be harmful because it may have been stored at the wrong temperature or humidity or other improper conditions, may degrade or lose potency, become contaminated, or may have been tampered with or handled improperly while outside of the legitimate supply chain.
The lot numbers, doses, and quantities of the stolen Advair Diskus inhalers are:
* Lot 9ZP2255 - NDC 0173-0696-00, Advair Diskus 250/50, 60 Dose, Exp: Sep 2010 (14,400 inhalers)
* Lot 9ZP3325 - NDC 0173-0697-00, Advair Diskus 500/50, 60 Dose, Exp: Sep 2010 (11,200 inhalers)
Patients who have products with these lot numbers should immediately stop using them, contact GlaxoSmithKline’s Customer Response Center at 888-825-5249, and follow-up with their physician or pharmacist to obtain a proper replacement.
Pharmacists and wholesalers who find Advair Diskus inhalers bearing these lot numbers should remove them from shelves and contact the FDA’s Office of Criminal Investigations (OCI) at 800-551-3989. The agency also is asking for the public's help in reporting any information regarding these inhalers, including suspicious or unsolicited offers for the Advair Diskus lots in question, to OCI or by visiting the OCI website.
-----
www.fayettefrontpage.com
Fayette Front Page
www.georgiafrontpage.com
Georgia Front Page
Follow us on Twitter: @GAFrontPage
at
8:42 AM
Labels: advair, asthma, discs, fayette front page, fda, georgia, georgia front page, stolen, warning
Monday, June 21, 2010
New Tobacco Regulations and FDA Rules Take Effect June 22
/PRNewswire/ -- Starting tomorrow (June 22), new regulations and FDA rules authorized by the Family Smoking and Prevention Act will further limit the tobacco industry's ability to deceive consumers with misleading marketing and labeling that imply "light," "mild" or "low-tar" cigarettes are safer, as well as other practices that make products more appealing to youth. The Act, which was overwhelmingly approved by Congress and signed into law by President Barack Obama one year ago, grants the U.S. Food and Drug Administration (FDA) authority to regulate tobacco products.
"It is not surprising that Marlboro Lights are the most popular brand in the nation. Decades of clever packaging, branding and other misinformation are intended to suggest that some tobacco products are not as harmful as others. The fact that they will no longer be available under that name is significant," said David Willoughby, CEO of ClearWay Minnesota(SM). "The anniversary of the law and new regulations offer a good reminder that tobacco use is still one of our most significant health concerns, costing Minnesota nearly $2 billion a year in health care costs. These changes are a step in the right direction."
On June 22, the following components of the Act will go into effect:
-- Prohibit terms such as "light," "low" and "mild" in all advertising,
labeling and marketing of existing cigarettes and smokeless tobacco
products. Evidence demonstrates that these terms can mislead consumers
into believing that certain products are safer.
-- Require larger, stronger warning labels on all smokeless tobacco
products and in advertisements. Though youth smoking is generally
decreasing, 15.6 percent of high school boys and 2.4 percent of high
school girls use smokeless tobacco, according to the Minnesota Youth
Tobacco and Asthma Survey.
-- FDA rules also will ban branded product tie-ins, such as t-shirts,
with cigarette and other tobacco purchases, and prohibit sales of
cigarettes in packages of fewer than 20 cigarettes. Some retailers
split packs, making cigarettes more affordable and accessible to
youth.
In response, tobacco companies have announced plans to use color-coded packaging to replace the terms "light," "low" and "mild." Lighter colors will signify light cigarettes. For example, Marlboro Lights are now Marlboro Golds.
"With its latest color scheme, the tobacco industry is continuing to use sophisticated marketing to hide the dangers of their products," Willoughby said. "But make no mistake: All cigarettes (whether light or gold) are harmful and a significant health risk. On June 22, choose to quit instead of choosing a color. QUITPLAN Services and other resources can help."
This year's new regulations build on changes that occurred under the Act in 2009, including:
-- Granting the FDA authority to issue tobacco product standards that
promote public health, such as removing or reducing harmful
ingredients.
-- Requiring companies to disclose tobacco product contents, as well as
changes in products and research about their health effects.
-- Banning all artificial or natural characterizing flavors other than
tobacco or menthol from all cigarettes and their component parts.
For more information on QUITPLAN Services, go to www.quitplan.com. For more information on the FDA, go to www.fda.gov.
-----
www.fayettefrontpage.com
Fayette Front Page
www.georgiafrontpage.com
Georgia Front Page
Follow us on Twitter: @GAFrontPage
at
9:27 AM
Labels: fayette front page, fda, georgia, georgia front page, health, marketing, regulate, tobacco
Tuesday, April 20, 2010
FDA Issues Statement on IOM Sodium Report
Today’s average sodium intake is several times what the body requires and its long-term effect on our health is very serious. Hypertension, or high blood pressure, affects one in three U.S. adults – nearly 75 million people aged 20 or older. An additional 50 million adults suffer from pre-hypertension. High blood pressure can increase the risk for heart attacks, strokes, heart failure, and kidney failure. Too much sodium in the daily diet is a major contributor to high blood pressure.
A new report from the Institute of Medicine this week concludes that national action is imperative to reduce the sodium content of foods if we are to make significant progress toward reducing the risk of hypertension and major cardiovascular events for Americans.
A story in today’s Washington Post leaves a mistaken impression that the FDA has begun the process of regulating the amount of sodium in foods. The FDA is not currently working on regulations nor have they made a decision to regulate sodium content in foods at this time.
Over the coming weeks, the FDA will more thoroughly review the recommendations of the IOM report and build plans for how the FDA can continue to work with other federal agencies, public health and consumer groups, and the food industry to support the reduction of sodium levels in the food supply. The Department of Health and Human Services will be establishing an interagency working group on sodium at the Department that will review options and next steps
Success in reducing sodium intake will require coordinated national action, with participation of all. We are encouraged by the fact that some food manufacturers have already begun or announced their commitment to reduce sodium levels in their products.
As a consumer, you can start lowering your sodium intake today by purchasing foods low in sodium, asking your grocer to carry more low-sodium products, and asking for low-sodium options at restaurants.
-----
www.fayettefrontpage.com
Fayette Front Page
www.georgiafrontpage.com
Georgia Front Page
Follow us on Twitter: @GAFrontPage
at
2:35 PM
Labels: diet, fayette, fayette front page, fayetteville, fda, georgia, georgia front page, health, hypertension, intake, peachtree city, risk, salt, sodium, tyrone
Monday, January 18, 2010
FDA Warns Consumers about Counterfeit Alli
/PRNewswire/ -- The U.S. Food and Drug Administration is today warning consumers about a counterfeit and potentially harmful version of Alli 60 mg capsules (120 count refill kit).
Preliminary laboratory tests conducted by GlaxoSmithKline (GSK) -- the maker of the FDA-approved over-the-counter weight-loss product -- revealed that the counterfeit version did not contain orlistat, the active ingredient in its product. Instead, the counterfeit product contained the controlled substance sibutramine. Sibutramine is a drug that should not be used in certain patient populations or without physician oversight. Sibutramine can also interact in a harmful way with other medications the consumer may be taking.
Consumers began reporting suspected counterfeit Alli to GSK in early December 2009. GSK has determined that the counterfeit product has been sold over the internet. However, there is no evidence at this time that the counterfeit Alli product has been sold through other channels, such as retail stores.
The counterfeit Alli product looks similar to the authentic product, with a few notable differences. The counterfeit Alli has:
-- Outer cardboard packaging missing a "Lot" code;
-- Expiration date that includes the month, day, and year (e.g.,
06162010); authentic Alli expiration date includes only the month and
year (e.g.,: 05/12);
-- Packaging in a plastic bottle that has a slightly taller and wider cap
with coarser ribbing than the genuine product;
-- Plain foil inner safety seal under the plastic cap without any printed
words; the authentic product seal is printed with "SEALED for YOUR
PROTECTION";
-- Contains larger capsules with a white powder, instead of small white
pellets.
Consumers who believe they have received counterfeit Alli are asked to contact the FDA's Office of Criminal Investigations (OCI) by calling 800-551-3989 or by visiting the OCI Web site (http://www.fda.gov/OCI).
Health care professionals and consumers are encouraged to report adverse events that may be related to the use of these counterfeit products to the FDA's MedWatch Program by phone at 1-800-FDA-1088, by fax at 1-800-FDA-0178, or by mail at: MedWatch, HF-2, FDA, 5600 Fishers Lane, Rockville, MD 20852-9787.
-----
www.fayettefrontpage.com
Fayette Front Page
www.georgiafrontpage.com
Georgia Front Page
Follow us on Twitter: @GAFrontPage
at
11:58 AM
Labels: alli, counterfeit, drugs, fayette, fayette front page, fda, georgia, georgia front page, sibutramine, warning, weight loss
Wednesday, October 14, 2009
New FDA Web Page Lists Disposal Instructions for Select Medicines
/PRNewswire/ -- The U.S. Food and Drug Administration today launched a Web page for consumers with information on how to dispose of certain drugs, including several high-potency opioids and other selected controlled substances. These medicines have the potential to be harmful, even deadly, in a single dose if taken by someone other than the intended person.
The FDA recommends that these medicines be disposed of by flushing down the sink or toilet. The goal is to keep them away from children and others who could be harmed by taking them accidentally.
Medicines not listed should be thrown away in the household trash after mixing them with some unpalatable substance, such as coffee grounds, and sealing them in a bag or other container. Another option is to dispose of them through drug take back programs, if federal and state law permit.
"The safe disposal of medicines from the home after they are no longer needed is an important concern for the FDA," said Douglas Throckmorton, M.D., deputy center director of FDA's Center for Drug Evaluation and Research.
All medicines listed have disposal instructions in their professional prescribing information; however, this information is targeted to health care professionals. The Web page provides clear instructions for consumers on whether a medicine should be flushed or disposed of in the trash.
Throckmorton also said, "The FDA is working with other groups to improve the use of several drug disposal methods, including drug take back programs. However, for some potent medicines that can cause harm or death if inadvertently taken by family members, the FDA currently recommends flushing them down the sink or toilet to immediately and permanently remove them from the home. Simple precautions like these can reduce the likelihood of accidental and potentially dangerous exposure to unused medicines."
The FDA worked with the White House Office of National Drug Control Policy (ONDCP) to develop the first consumer guidance for proper disposal of prescription drugs. The ONDCP federal guidelines were first issued in February 2007.
-----
www.fayettefrontpage.com
Fayette Front Page
www.georgiafrontpage.com
Georgia Front Page
at
2:09 PM
Labels: atlanta, disposal, fayette front page, fda, flush, georgia, georgia front page, medicines, recommendations, web
Tuesday, September 22, 2009
FDA: Philips Lifeline Issues Safety Alert for Lifeline Pendant Personal Help Buttons
The U.S. Food and Drug Administration today cautioned users of personal emergency response buttons worn around the neck of a potential choking hazard associated with this product.
The FDA is aware of at least six reports between 1998 and 2009 of serious injury or death, including three deaths in the United States and one in Canada, from choking after the cord on the Philips Lifeline Personal Help Button became entangled on other objects worn around the neck.
There are more than 750,000 users of these devices in the United States and Canada. By pushing the “help” button on the device when in distress, users can call for emergency assistance to their home. According to Philips Lifeline, the device is used primarily by seniors living independently, who feel they are at risk for falls or other medical emergencies.
The Lifeline pendant button is intentionally designed to not break away when tugged, which prevents the button from accidentally falling off. However, because it does not break away, there is a risk of choking, including the possibility of serious injury or death. Risks are greater for those with mobility limitations or for those who use wheelchairs, walkers, beds with guard rails, or other objects that could entangle with a neck cord.
Philips Lifeline is currently sending letters to its 750,000 customers and has changed the labeling of this product to include a warning against the potential choking hazard.
The FDA recommends that users consult their health care providers to determine which style of emergency button, including those that are worn on the wrist, is most beneficial for them.
These widely used devices provide critical and immediate access to emergency care for those at risk of falls or who may be more likely to need outside assistance. While the number of adverse events reported is small compared to the number of people who use this device, the severity of these events is of concern. It remains important that users, along with their health care providers, assess the options provided by each style of button, and choose the option that best fits their condition.
-----
www.fayettefrontpage.com
Fayette Front Page
www.georgiafrontpage.com
Georgia Front Page
www.artsacrossgeorgia.com
Arts Across Georgia
at
12:33 PM
Labels: atlanta, button, choking, death, emergency, fayette front page, fayetteville, fda, georgia, georgia front page, lifeline, neck, peachtree city, response, senior, tyrone
Monday, March 23, 2009
Plan B Ruling Endangers Health and Parental Rights
/PRNewswire-USNewswire/ -- Today US District Judge Edward R. Korman ordered the FDA to make the morning after pill available to 17-year-old minor girls without a physician's visit or prescription and without parental consent. Judge Korman also asked the FDA to consider making the drug available to girls and women regardless of age.
Chris Gacek, Family Research Council's Senior Fellow for Regulatory Affairs, released the following statement:
"This ruling jeopardizes girls' health and the ability of parents to care for their daughters' physical and emotional well-being. Judge Korman has accepted lock, stock, and barrel all of the claims of a political ideology promoting sexual license for teens.
"Now some minor girls will be able to obtain this drug without any guidance from a doctor and without any parental supervision. We lack scientific studies on the long-term effects of Plan B with respect to high dosage and repeated use in both women and adolescents. Also, research from Scotland in the 1990s indicated that the increased use of the morning after pill did not decrease abortion rates.
"There is a real danger that Plan B may be given to women, especially sexually abused women and minors, under coercion or without their consent. Interaction with medical professionals is a major screening and defense mechanism for victims of sexual abuse. The availability of Plan B over-the-counter also bypasses the routine medical care of sexually active girls and women, which is important to allow screening for other health conditions, including sexually transmitted diseases."
-----
www.fayettefrontpage.com
Fayette Front Page
www.georgiafrontpage.com
Georgia Front Page
Treatment Option In Metastatic Breast Cancer
(NAPSI)-Breast cancer is the second leading cause of cancer deaths in women in the United States. Metastatic breast cancer is the most advanced stage of breast cancer.
For more than 60 years, chemotherapy has been, and continues to be, one of the foundations in the treatment of cancer. Most breast cancer patients will receive chemotherapy at some time during the course of their disease. However, resistance to chemotherapy is a major cause of treatment failure in patients with metastatic breast cancer. Drug resistance is associated with >90 percent of treatment failures in patients with metastatic breast cancer.
In October 2007, the U.S. Food and Drug Administration (FDA) granted approval of the first epothilone chemotherapy, IXEMPRA™ (ixabepilone), as a monotherapy for the treatment of patients with metastatic or locally advanced breast cancer resistant or refractory to anthracyclines, taxanes, and capecitabine. Anthracycline resistance is defined as progression while on therapy or within six months in the adjuvant setting or three months in the metastatic setting. Taxane resistance is defined as progression while on therapy or within 12 months in the adjuvant setting or four months in the metastatic setting. IXEMPRA was also granted approval in combination with capecitabine for the treatment of patients with metastatic or locally advanced breast cancer resistant to treatment with an anthracycline and a taxane, or whose cancer is taxane resistant and for whom further anthracycline therapy is contraindicated.
Your healthcare provider should do blood tests to check your liver function before receiving IXEMPRA and as needed while receiving IXEMPRA. If blood tests show that you have liver problems, do not receive injections of IXEMPRA along with the medicine capecitabine. With liver problems, taking these medicines together could increase your chance of serious infection and death due to a very low white blood cell count (neutropenia).
The most common side effects with IXEMPRA used alone or with capecitabine may include: tiredness; loss of appetite; disorders of toenails and fingernails; hair loss; fever; decreased red blood cells (anemia); joint and muscle pain; headache; decreased platelets (thrombocytopenia); nausea, vomiting, diarrhea, constipation, and abdominal pain; sores on the lip, in the mouth and esophagus; tender, red palms and soles of feet (hand-foot syndrome) that look like a sunburn, the skin may become dry and peel or feel numb and tingle.
"Previously, patients with aggressive metastatic or locally advanced breast cancer no longer responding to currently available chemotherapies had limited treatment options," said Linda Vahdat, M.D., Associate Professor of Clinical Medicine, Director Breast Cancer Research Program, Weill Cornell Medical Center. "The approval of IXEMPRA means that we have an important option for patients with metastatic breast cancer who have rapidly progressed through currently approved chemotherapies."
"
Important Safety Information
Indications and Usage:
IXEMPRA™ (ixabepilone) is a prescription medicine used to treat breast cancer, when certain other medicines have not worked or no longer work. IXEMPRA is used alone or with another cancer medicine called capecitabine.
Important Safety Information about IXEMPRA
Your healthcare provider should do blood tests to check your liver function before receiving IXEMPRA and as needed while receiving IXEMPRA. If blood tests show that you have liver problems, do not receive injections of IXEMPRA along with the medicine capecitabine. With liver problems, taking these medicines together could increase your chance of serious infection and death due to a very low white blood cell count (neutropenia).
You should not receive IXEMPRA (ixabepilone), if you are:
• Allergic to a medicine that contains Cremophor® EL1 or polyoxyethylated castor oil.
• Have low white blood cell or platelet counts.
Before you receive treatment with IXEMPRA, a medicine given by injection directly into your vein (intravenous infusion), you should tell your healthcare provider about all your medical conditions, including if you:
• Have liver problems.
• Have heart problems or a history of heart problems.
• Have had an allergic reaction to IXEMPRA. To lower the chance of an allergic reaction, you will receive other medicines about 1 hour before each dose of IXEMPRA.
• Are pregnant or plan to become pregnant. IXEMPRA may harm your unborn baby.
• Are breast-feeding. It is not known if IXEMPRA passes into breast milk.
• Take any medicines, including prescription and non-prescription medicines, vitamins and herbal supplements, including St. John's Wort. IXEMPRA and certain other medicines may affect each other causing side effects.
• Have diabetes.
• Have had numbness, tingling, or burning in the hands or feet (neuropathy)
Things to avoid while taking IXEMPRA:
• IXEMPRA contains alcohol and may cause dizziness or drowsiness. Avoid activities that may be dangerous, such as driving or operating machinery.
• Do not drink grapefruit juice because it may cause you to have too much IXEMPRA in your blood which can lead to side effects.
IXEMPRA may cause serious side effects. Tell your healthcare provider if you have the following:
• Numbness, tingling, or burning in the hands or feet (neuropathy). These symptoms may be new or get worse and often occur early during treatment. Your dose of IXEMPRA may need to be
decreased, stopped until your symptoms get better, or totally stopped.
• White blood cells help protect the body from infections caused by bacteria. If you get a fever or infection when your white blood cells are very low, you can become seriously ill and die. Symptoms
may include, fever (temperature over 100.5), chills, cough, burning, or pain when you urinate. You may need treatment in the hospital with antibiotic medicines.
• Severe allergic reactions can occur and in rare cases cause death. Allergic reactions are most likely to occur when IXEMPRA is being injected. You may experience itching, hives, rash, flushed
face, sudden swelling of face, throat or tongue, chest tightness, trouble breathing, feel dizzy or faint, feel your heart beating (palpitations).
• Chest pain, difficulty breathing, palpitations, or unusual weight gain can be caused by decreased blood flow to the heart, problems with heart function and abnormal heart beat.
The most common side effects with IXEMPRA used alone or with capecitabine may include: tiredness; loss of appetite; disorders of toenails and fingernails; hair loss; fever; decreased red blood cells
(anemia); joint and muscle pain; headache; decreased platelets (thrombocytopenia); nausea, vomiting, diarrhea, constipation, and abdominal pain; sores on the lip, in the mouth and esophagus; ten
der, red palms and soles of feet (hand-foot syndrome) that look like a sunburn, the skin may become dry and peel or feel numb and tingle.
If you have any questions about your health or medicines, talk to your healthcare provider.
Please see accompanying full prescribing information including boxed WARNING regarding liver disease.
1Cremophor is a registered trademark of BASF AG.
Brought to you by Bristol-Myers Squibb.
-----
www.fayettefrontpage.com
Fayette Front Page
www.georgiafrontpage.com
Georgia Front Page
at
2:16 PM
Labels: atlanta, breast cancer, chemotherapy, fayette front page, fda, georgia, georgia front page, ixempra, options, treatment